Mounjaro 2.5mg KwikPen contains Tirzepatide, a dual GIP and GLP-1 receptor agonist used for type 2 diabetes management. It is taken once a week and helps with weight loss and blood sugar control.

Brand Name: Mounjaro

Composition: Tirzepatide

Mechanism of Action:

A dual GIP and GLP-1 receptor agonist, tirzepatide aids in controlling blood sugar levels in people with type 2 diabetes. It functions by slowing stomach emptying, which raises satiety and may aid in weight loss, decreasing glucagon levels to lower blood sugar, and increasing insulin production in response to meal consumption.

Uses:

·       Type-2 Diabetes Mellitus

·       Weight Management

Dosage and Administration:

·       Mounjaro 2.5 mg KwikPen is injected subcutaneously once a week (abdomen, thigh, or upper arm), with the area of injection changing each time.

·       Begin with 2.5mg weekly for 4 weeks, then increase to 5mg weekly; additional 2.5mg increases may be made every 4 weeks up to 15mg.

·       It can be administered at any time of day, with or without food.

·       If a dose is missed, it should be given within four days; otherwise, ignore it and resume the next planned dose.

Side Effects:

·       Nausea

·       Vomiting

·       Diarrhea

·       Constipation

·       Decreased appetite

·       Injection site reactions (Itching, Rashes)

·       Hypoglycemia

Safety Advise:

Lungs  

The safety of Mounjaro for individuals with lung issues is uncertain. Kindly speak with your healthcare provider.

Liver  

The safety of Mounjaro for individuals with liver issues is uncertain. Kindly speak with your healthcare provider.

Kidney  

The safety of Mounjaro for individuals with Kidney issues is uncertain. Kindly speak with your healthcare provider.

Pregnancy  

Mounjaro should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using Mounjaro while nursing is most likely dangerous. Kindly speak with your healthcare provider. 

Storage:

Avoid freezing the Mounjaro KwikPen and keep it in a refrigerator between 2°C and 8°C. After usage, it can be stored for 21 days at room temperature (up to 30°C) under protection from heat and light.

How to use this Medication?

This drug is administered subcutaneously. You'll learn how to prepare and administer it. It is administered once every seven days, or once a week. Unless instructed otherwise by your healthcare provider, continue taking it.

You should inject this medication and insulin separately if you take both together. Don't combine them. Avoid administering the shots directly close to one another. With every injection, rotate the injection sites.

References:

1.   Baker DE, Walley K, Levien TL. Tirzepatide. Hospital Pharmacy. 2023 Jun;58(3):227-43.

2.  Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022 Aug;65(8):1251-61.

3.  Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022 Jul 21;387(3):205-16.

4.  Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules. 2022 Jul 5;27(13):4315.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Eli Lilly and Company India Pvt Ltd

Address: Plot# 92, Sector 32, Institutional Area, Gurgaon-122001, HARYANA, INDIA

Country of origin: United states

Frequently Asked Questions:

1. What is Mounjaro 2.5mg KwikPen used for?
Mounjaro 2.5mg KwikPen (Tirzepatide) is an introductory starting dose prescribed for the management of Type 2 diabetes. It may help support blood sugar regulation and, in some patients, may be associated with modest weight changes. Individual outcomes may vary. Please consult your doctor to understand whether this medication is appropriate for you.

2. Why is 2.5mg the starting dose of Mounjaro?
The 2.5mg dose is typically used as an initial starting point to allow the body to gradually adjust to Tirzepatide. This approach may help reduce the likelihood and severity of gastrointestinal side effects such as nausea or vomiting, though individual tolerability may differ.

3. How is the Mounjaro KwikPen administered?
The KwikPen is designed to deliver a subcutaneous (under-the-skin) injection once weekly. Common injection sites may include the abdomen, thigh, or upper arm, as recommended by your healthcare provider.

4. How long should I stay on the 2.5mg dose?
Patients are typically maintained on the 2.5mg dose for approximately 4 weeks before a physician considers a dose increase. The decision to escalate the dose depends on individual tolerance and blood sugar response, as assessed by your doctor.

5. Is the KwikPen easy to use?
The KwikPen is a prefilled, disposable auto-injector designed for self-administration. Many patients find it relatively straightforward to use, though ease of use may vary. It is important to follow the instructions provided in the product leaflet or as demonstrated by your healthcare professional before using it independently.

6. What are the possible side effects of Mounjaro 2.5mg?
Some patients may experience side effects such as:
•         Nausea
•         Decreased appetite
•         Diarrhoea
•         Vomiting
These are generally reported as mild. Not every patient will experience these effects, and they may lessen as the body adjusts. Consult your doctor if any side effects are persistent or concerning.

7. Can Mounjaro 2.5mg contribute to weight loss?
While Mounjaro is primarily indicated for Type 2 diabetes, some studies suggest that Tirzepatide at various doses, including 2.5mg, may be associated with weight changes in certain patients. Weight loss is not guaranteed and can vary considerably. Please discuss realistic expectations with your physician.

8. Who should avoid using the Mounjaro KwikPen?
Mounjaro may not be appropriate for:
•         Individuals with a personal or family history of medullary thyroid carcinoma (MTC)
•         Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
•         Those with known hypersensitivity to Tirzepatide or any component of the formulation
This is not an exhaustive list. Your doctor will assess your suitability before prescribing.

9. How should the Mounjaro KwikPen be stored?
Unused pens should generally be stored in a refrigerator (2°C–8°C). A pen currently in use may be stored at room temperature (up to 30°C) for a limited period as per manufacturer guidance. Keep away from heat and direct light. Always refer to the product label for specific instructions.

10. Is a prescription required for Mounjaro 2.5mg KwikPen?
Yes. This is a prescription-only medication and must be obtained through a licensed pharmacy with a valid prescription from a qualified healthcare professional.

Medical Disclaimer:
Mounjaro 2.5mg KwikPen is a prescription-only medicine and must be used strictly under the supervision and guidance of a qualified healthcare professional. Do not self-medicate, alter the dosage, or discontinue use without consulting your doctor. The information provided here is for educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Individual results, benefits, and risks may vary. Always consult your physician before starting, changing, or stopping any medication.